Payment overview · 2025
General Payments
$231.72
7 reported records · 4 companies
Healthcare provider profile · identity verified
Eric Alan Payne, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKLINTON, LA · NPI 1356306864
Verified facts
What the public records show
CMS Open Payments records show Eric Alan Payne, MD received $231.72 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 70.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.40 | 70.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.37 | 10.9% | 1 | 2025 |
| Checkpoint Surgical, Inc | Unresolved — no canonical attribution shown | $22.83 | 9.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.12 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $231.72 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ALLODERM Normalized: alloderm |
Device | ABBVIE INC. | $96.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.40 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| Checkpoint Stimulators Normalized: checkpoint stimulators |
Device | Checkpoint Surgical, Inc | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 305 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 64 |
| Lorazepam | Lorazepam | 235 | 37 |
| Alprazolam | Alprazolam | 194 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 58 |
| Oxycodone Hcl | Oxycodone Hcl | 178 | 17 |
| Gabapentin | Gabapentin | 163 | 53 |
| Fluconazole | Fluconazole | 162 | 63 |
| Potassium Chloride | Potassium Chloride | 156 | 42 |
| Clonazepam | Clonazepam | 152 | 18 |
| Metformin Hcl | Metformin Hcl | 150 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 40 |
| Lisinopril | Lisinopril | 124 | 33 |
| Losartan Potassium | Losartan Potassium | 124 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 21 |
| Furosemide | Furosemide | 117 | 34 |
| Simvastatin | Simvastatin | 114 | 24 |
| Ondansetron Odt | Ondansetron | 110 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 32 |
| Tramadol Hcl | Tramadol Hcl | 103 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 101 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 28 |
| Alendronate Sodium | Alendronate Sodium | 99 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 30 |
| Montelukast Sodium | Montelukast Sodium | 86 | 24 |
| Azithromycin | Azithromycin | 84 | 65 |
| Ozempic | Semaglutide | 81 | 21 |
| Ibuprofen | Ibuprofen | 80 | 24 |
| Pregabalin | Pregabalin | 80 | 17 |
| Omeprazole | Omeprazole | 75 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 75 | 18 |
| Temazepam | Temazepam | 74 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 73 | 17 |
| Carisoprodol | Carisoprodol | 71 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 26 |
| Armour Thyroid | Thyroid,pork | 68 | 15 |
| Linzess | Linaclotide | 66 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 15 |
| Meloxicam | Meloxicam | 55 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 25 |
| Diazepam | Diazepam | 49 | suppressed |
| Jardiance | Empagliflozin | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 14 |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 36 |
| Zaleplon | Zaleplon | 43 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | 11 |
| Eliquis | Apixaban | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 12 |
| Carvedilol | Carvedilol | 30 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 13 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 23 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $231.72 · 7 records | ABBVIE INC. | ALLODERM, Checkpoint Stimulators, Kerendia, NURTEC ODT, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error